1.  The previous year''s figures have been recast/regrouped wherever
 necessary in order to conform to current year''s presentation.
 
 2.  Estimated amount of contracts remaining to be executed on Capital
 Account and not provided for (net of advances) Rs.218.93 crore (Previous
 year Rs.255.75 crore).
 
 3.  Contingent Liabilities
 
 i.  Financial and performance guarantees given by banks on behalf of
 the Company Rs.59.97 crore (Previous year Rs.63.72 crore).  
 
 ii.  Letters of credit issued by banks on behalf of the Company Rs.36.54
 crore (Previous year Rs.42.60 crore).
 
 iii.  Refund of Technical Know-how/fees on account of non compliance of
 certain obligations as per respective agreements Rs.7.45 crore (Previous
 year Rs.15.38 crore)
 
 iv.  Income Tax Rs.204.44 crore (Previous year Rs.115.35 crore) The above
 Rs.204.44 crore represents claims where the Company has f led appeals and
 expects a favourable outcome, based on decisions in earlier assessment
 years.
 
 v.  Excise Duty/Service Tax Rs.49.23 crore (Previous year Rs.47.80 crore).
 
 The above claims were based on decisions in earlier years where the
 Company is of the opinion that the demand is not sustainable.
 
 vi.  Sales Tax Rs.4.02 crore (Previous year Rs.0.86 crore).
 
 vii.  Other claims against the Company not acknowledged as debts Rs.1.64
 crore (Previous year Rs.4.11 crore).
 
 4.  The Government of India has served demand notices in March 1995 and
 May 1995 on the Company in respect of six bulk drugs, claiming that an
 amount of Rs.5.46 crore along with interest due thereon is payable into
 the DPEA under the Drugs (Prices Control) Order, 1979 on account of
 alleged unintended benefit enjoyed by the Company.  The Company has f
 led its replies to the notices and has contended that no amount is
 payable into the DPEA under the Drugs (Prices Control) Order, 1979.
 
 5.  In 2003, the Company received notice of demand from the National
 Pharmaceutical Pricing Authority, Government of India on account of
 alleged overcharging in respect of certain drugs under the Drug Price
 Control Order. This was contested before the jurisdictional High Courts
 wherein it was held in favour of the Company.
 
 The orders were challenged before the Hon''ble Supreme Court by the
 Government. The Hon''ble Supreme Court by separate orders restored the
 matter to the jurisdictional High Court for interpreting the Drug
 Policy on the basis of directions and principles laid down by them and
 also restrained the Government from taking any coercive action against
 the Company. The Company has been legally advised that on the basis of
 these orders there is no probability of demand crystallising. Hence, no
 provision is considered necessary in respect of notice of demand
 aggregating to Rs.1230.28 crore (inclusive of interest) for the period
 July 1995 to April 2009.
 
 6.  The net difference in foreign exchange credited to the profit and
 Loss Account is Rs.12.86 crore (Previous year debit Rs.63.89 crore).
 
 7. The Ministry of Corporate Affairs, Government of India vide its
 General Notification No. S.O. 301(E) dated 8th February 2011 issued
 under section 211(3) of the Companies Act, 1956 has exempted certain
 classes of companies from disclosing certain information in their Prof
 -it and Loss Account. The Company being an ‘Export Oriented Company'' is
 entitled to the exemption. Accordingly, disclosures mandated by
 paragraphs 3(i)(a), 3(ii)(a), 3(ii)(b) and 3(ii)(d) of Part II,
 Schedule VI to the Companies Act,1956 have not been provided.
 
 8.  Related Party Disclosures
 
 i.  The related parties are as under:
 
 a.  Subsidiary Companies including step-down subsidiary and associate
 companies:
 
 Sr.  Name of the Company With effect from No.
 
 Subsidiaries (held directly)
 
 1 Cipla FZE 04/10/2006
 
 2 Goldencross Pharma Pvt. Ltd.  14/05/2010
 
 3 Cipla (Mauritius) Ltd.  27/01/2011
 
 4 Meditab Specialities Pvt. Ltd.  01/10/2010
 
 Subsidiaries (held indirectly)
 
 5 Cipla (UK) Ltd.  27/01/2011
 
 6 Cipla-Oz Pty Ltd.  04/03/2011
 
 7 STD Chemicals Ltd.  27/01/2011
 
 8 Medispray Laboratories Pvt. Ltd.  01/10/2010
 
 9 Four M Propack Pvt. Ltd.  14/05/2010
 
 10 Sitec Labs Pvt. Ltd.  01/10/2010
 
 11 Meditab Holdings Ltd.  01/10/2010
 
 12 Meditab Pharmaceuticals South Africa (Pty) Ltd.  14/01/2011
 
 13 Meditab Specialities New Zealand Ltd.  21/01/2011
 
 Associates
 
 14 Quality Chemicals Industries Ltd.  01/10/2010
 
 15 Stempeutics Research Pvt. Ltd.  01/10/2010
 
 16 Desano Holdings Ltd.  01/10/2010
 
 17 Shanghai Desano Chemical Pharmaceutical Co. Ltd.  01/10/2010
 
 18 Shanghai Desano Pharmaceutical Investment Co. Ltd.  01/10/2010
 
 b.  Key Management Personnel:
 
 1.  Dr. Y. K. Hamied – Chairman and Managing Director
 
 2.  Mr. M. K. Hamied – Joint Managing Director
 
 3.  Late Mr. Amar Lulla – Joint Managing Director (up to13th December
 2010)
 
 4.  Mr. S. Radhakrishnan – Whole-time Director (w.e.f. 12th November
 2010)
 
 c.  Entities over which Key Management Personnel exercise significant
 influence – Cipla Public Charitable Trust, Cipla Cancer and AIDS
 Foundation, Mediorals Laboratories Pvt. Ltd., Good Earth Remedies Ltd.,
 Globus Healthcare Ltd., Advanced Remedies Pvt. Ltd., Medispray
 Laboratories Pvt. Ltd. (up to 19th August 2010), Goldencross Pharma
 Pvt. Ltd. (up to 13th May 2010), Okasa Pvt. Ltd. & Okasa Pharma Pvt.
 Ltd. (w.e.f.  1st March 2011)
 
 Disclosures in respect of material related party transactions during
 the year :
 
 a.  Receipts include interest received from Cipla FZE Rs.Nil (Previous
 year Rs.0.19 crore), Goldencross Pharma Pvt.  Ltd. Rs.1.54 crore (Previous
 year Rs.0.55 crore) and Meditab Specialities Pvt. Ltd. Rs.0.19 crore
 (Previous year Rs.Nil)
 
 b.  Loan repayment from Cipla FZE Rs.Nil (Previous year Rs.17.76 crore),
 Goldencross Pharma Pvt. Ltd. Rs.76.55 crore (Previous year Rs.Nil) and
 Meditab Specialities Pvt. Ltd. Rs.102.70 crore (Previous year Rs.Nil)
 
 c.  Investment-Equity into Cipla FZE Rs.Nil (Previous year Rs.17.42 crore),
 Goldencross Pharma Pvt. Ltd. Rs.191.12 crore (Previous year Rs.Nil) ,
 Meditab Specialities Pvt. Ltd. Rs.133.72 crore (Previous year Rs.Nil) and
 Cipla (Mauritius) Ltd.  Rs.3.16 crore (Previous year Rs.Nil)
 
 d.  Loans given to Goldencross Pharma Pvt. Ltd. Rs.27.00 crore (Previous
 year Rs.5.82 crore) and Meditab Specialities Pvt. Ltd. Rs.225.67 crore
 (Previous year Rs.Nil)
 
 e.  Remuneration paid to Dr. Y.K. Hamied Rs.6.03 crore (Previous year
 Rs.8.53 crore), Mr. M.K. Hamied Rs.6.10 crore (Previous year Rs.8.11 crore),
 Mr. Amar Lulla Rs.3.91 crore (Previous year Rs.12.87 crore) and Mr. S.
 Radhakrishnan Rs.2.56 crore (Previous year Rs.Nil)
 
 f.  Deposit repaid to Dr. Y.K. Hamied Rs.Nil (Previous year Rs.38.00
 crore).
 
 g.  Interest paid to Dr. Y.K. Hamied Rs.Nil (Previous year Rs.3.13 crore).
 
 h. Purchase of goods from Goldencross Pharma Pvt. Ltd. Rs.169.25 crore
 (Previous year Rs.18.45 crore), Medispray Laboratories Pvt. Ltd. Rs.11.40
 crore (Previous year Rs.4.88 crore), Advanced Remedies Pvt. Ltd. Rs.0.32
 crore (Previous year Rs.Nil), Mediorals Laboratories Pvt. Ltd. Rs.1.16
 crore (Previous year Rs.Nil), Meditab Specialities Pvt. Ltd. Rs.63.52 crore
 (Previous year Rs.Nil), Four M Propack Pvt. Ltd. Rs.7.99 crore (Previous
 year Rs.Nil) , Shanghai Desano Chemical Pharmaceutical Co. Ltd. Rs.11.96
 crore (Previous year Rs.Nil) , Shanghai Desano Pharmaceutical Investment
 Co. Ltd. Rs.174.21 crore (Previous year Rs.Nil) , Okasa Pharma Pvt. Ltd.
 Rs.3.21 crore (Previous year Rs.Nil) and Okasa Pvt. Ltd. Rs.10.61 crore
 (Previous year Rs.Nil) .
 
 i. Processing charges paid to Goldencross Pharma Pvt. Ltd. Rs.2.89 crore
 (Previous year Rs.1.04 crore), Mediorals Laboratories Pvt. Ltd. Rs.2.63
 crore (Previous year Rs.0.94 crore), Medispray Laboratories Pvt. Ltd.
 Rs.9.57 crore (Previous year Rs.0.84 crore), Advanced Remedies Pvt. Ltd.
 Rs.2.61 crore (Previous year Rs.1.03 crore), Meditab Specialities Pvt. Ltd.
 Rs.15.09 crore (Previous year Rs.Nil), Sitec Labs Pvt. Ltd. Rs.29.46 crore
 (Previous year Rs.Nil), Okasa Pharma Pvt. Ltd. Rs.0.84 crore (Previous year
 Rs.Nil), STD Chemicals Ltd. Rs.0.79 crore (Previous year Rs.Nil) , Cipla(UK)
 Ltd. Rs.0.37 crore (Previous year Rs.Nil) and Cipla-Oz Pty Ltd. Rs.0.34 crore
 (Previous year Rs.Nil) and Okasa Pvt. Ltd. Rs.0.30 crore (Previous year
 Rs.Nil).
 
 j. Sale of goods to Goldencross Pharma Pvt. Ltd. Rs.8.43 crore (Previous
 year Rs.Nil), Meditab Specialities Pvt.  Ltd. Rs.2.76 crore (Previous year
 Rs.Nil), Four M Propack Pvt. Ltd. Rs.0.05 crore (Previous year Rs.Nil),
 Medispray Laboratories Pvt. Ltd. Rs.14.91 crore (Previous year Rs.Nil),
 Advanced Remedies Pvt. Ltd. Rs.0.14 crore (Previous year Rs.Nil), Mediorals
 Laboratories Pvt. Ltd. Rs.0.37 crore (Previous year Rs.Nil), Sitec Labs
 Pvt. Ltd. Rs.0.41 crore (Previous year Rs.Nil), Okasa Pharma Pvt. Ltd.
 Rs.0.42 crore (Previous year Rs.Nil), Okasa Pvt. Ltd. Rs.1.55 crore (Previous
 year Rs.Nil), Shanghai Desano Chemical Pharmaceutical Co.Ltd. Rs.56.97
 crore (Previous year Rs.Nil) and Quality Chemicals Industries Ltd. Rs.92.36
 crore (Previous year Rs.Nil).
 
 k.  Advance paid against services to Stempeutics Research Pvt. Ltd.
 Rs.6.10 crore (Previous year Rs.Nil).
 
 l. Processing charges received from Meditab Specialities Pvt. Ltd.
 Rs.0.23 crore (Previous year Rs.Nil), Medispray Laboratories Pvt. Ltd.
 Rs.1.34 crore (Previous year Rs.Nil), Advanced Remedies Pvt. Ltd.
 Rs.0.01crore (Previous year Rs.Nil), Mediorals Laboratories Pvt. Ltd. Rs.0.03
 crore (Previous year Rs.Nil), Okasa Pharma Pvt. Ltd. Rs.0.05 crore
 (Previous year Rs.Nil) and Okasa Pvt. Ltd. Rs.0.03 crore (Previous year
 Rs.Nil).
 
 m.  Donations made to Cipla Public Charitable Trust Rs.0.41 crore
 (Previous year Rs.0.40 crore).
 
 n. Purchase of Shares from Good Earth Remedies Ltd. Rs.0.51 crore
 (Previous year Rs.Nil) and from Globus Healthcare Ltd. Rs.0.51 crore
 (Previous year Rs.Nil).
 
 o. Rent paid to Okasa Pvt. Ltd. Rs.0.03 crore (Previous year Rs.Nil) and
 Medispray Laboratories Pvt. Ltd. Rs.45,000 (Previous year Rs.Nil).
 
 p. Outstanding payables as on 31st March 2011 include Goldencross
 Pharma Pvt. Ltd. Rs.5.63 crore (Previous year Rs.3.90 crore), Medispray
 Laboratories Pvt. Ltd. Rs.4.55 crore (Previous year Rs.13.60 crore),
 Mediorals Laboratories Pvt. Ltd. Rs.0.38 crore (Previous year Rs.Nil),
 Advanced Remedies Pvt. Ltd. Rs.0.02 crore (Previous year Rs.8.89 crore),
 Four M Propack Pvt. Ltd. Rs.1.23 crore (Previous year Rs.Nil), Sitec Labs
 Pvt. Ltd. Rs.7.69 crore (Previous year Rs.Nil), Okasa Pharma Pvt. Ltd.
 Rs.12.12 crore (Previous year Rs.Nil), Okasa Pvt. Ltd. Rs.9.72 crore
 (Previous year Rs.Nil), Shanghai Desano Chemical Pharmaceutical Co.Ltd.
 Rs.7.13 crore (Previous year Rs.Nil), Shanghai Desano Pharmaceutical
 Investment Co.Ltd. Rs.20.13 crore (Previous year Rs.Nil), STD Chemicals
 Ltd. Rs.0.79 crore (Previous year Rs.Nil), Cipla(UK) Ltd. Rs.0.37 crore
 (Previous year Rs.Nil) and Cipla-Oz Pty Ltd. Rs.0.34 crore (Previous year
 Rs.Nil).
 
 q. Outstanding Receivables as on 31st March 2011 include Goldencross
 Pharma Pvt. Ltd. Rs.Nil (Previous year Rs.69.21 crore) , Meditab
 Specialities Pvt. Ltd. Rs.51.33 crore (Previous year Rs.Nil), Medispray
 Laboratories Pvt. Ltd.  Rs.12.48 crore (Previous year Rs.Nil), Mediorals
 Laboratories Pvt. Ltd. Rs.0.21 crore (Previous year Rs.Nil) and Sitec Labs
 Pvt. Ltd. Rs.0.54 crore (Previous year Rs.Nil), Okasa Pharma Pvt. Ltd.
 Rs.6.03 crore (Previous year Rs.Nil), Okasa Pvt. Ltd. Rs.15.10 crore
 (Previous year Rs.Nil) Shanghai Desano Chemicals Pharmaceutical Co. Ltd.
 Rs.56.09 crore (Previous year Rs.Nil), Shanghai Desano Pharmaceutical
 Investment Co.Ltd. Rs.1.14 crore (Previous year Rs.Nil) and Quality
 Chemicals Industries Ltd. Rs.39.29 crore (Previous year Rs.Nil).
 
 9.  In accordance with AS-17 Segment Reporting, Segment information
 has been given in the Consolidated Financial Statements of Cipla Ltd.,
 and therefore, no separate disclosure on segment information is given
 in these financial statements.
 
 10.  The Company has identified Micro, Small and Medium Enterprises on
 the basis of information made available during the year by the
 respective suppliers or vendors of the Company.
 
 11. Employee benefits
 
 i.  Short Term Employee benefits
 
 All employee benefits payable wholly within twelve months of rendering
 the service are classified as short term employee benefits. benefits
 such as salaries, wages, short term compensated absences, etc., and the
 expected cost of bonus, ex-gratia are recognised in the period in which
 the employee renders the related service.
 
 ii.  Long Term Employee benefits
 
 The disclosures as per the revised AS-15 are as under:
 
 a.  Brief description of the Plans
 
 The Company''s defined contribution plan is Employees'' Pension Scheme
 (under the provisions of Employees'' Provident Funds and Miscellaneous
 Provisions Act, 1952) since the Company has no further obligation
 beyond making the contributions.
 
 The Company has two schemes for long term benefits namely, Provident
 Fund and Gratuity:
 
 - The Provident Fund plan, a funded scheme is operated by Company''s
 Provident Fund Trust, which is recognised by the Income Tax authorities
 and administered through trustees/appropriate authorities. The Guidance
 note on Implementing the revised AS-15, Employee benefits (revised
 2005) issued by Accounting Standards Board (ASB) states benefit
 involving employer established provident funds, which require interest
 shortfalls to be recompensed, are to be considered as defined benefit
 plans. Pending the issuance of the guidance note from the Actuarial
 Society of India, the Company''s actuary has expressed an inability, to
 reliably measure provident fund liabilities.  Accordingly, the Company
 is unable to present the related information.
 
 - The Company provides for gratuity, a defined benefit plan based on
 actuarial valuation as of the Balance Sheet date, based upon which, the
 Company contributes all the ascertained liabilities to the Insurer
 Managed Funds.
 
 The employees of the Company are also entitled to leave encashment and
 compensated absences as per the Company''s policy.
 
 12. During the year, the Company acquired an industrial undertaking at
 Kurkumbh on slump sale basis for a consideration of Rs.30.64 crore.
 Consequently, the Goodwill of Rs.60,461 arising on this transaction has
 been amortized in entirety during the year.